Related Content
- FDA approves Merck's Gardasil for prevention of anal cancer
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Walgreens allies with HHS to launch free flu shot outreach to disadvantaged
- Walgreens launches high-impact push in support of World AIDS Day campaign
- FDA approves Novartis drug for high blood pressure treatment
PRINCETON, N.J. The Food and Drug Administration has approved an additional use for a hepatitis drug.
Bristol-Myers Squibb announced Monday the approval of Baraclude (entecavir) as a treatment for chronic hepatitis B in adults with decompensated liver disease. The drug already is approved for adults with evidence of active viral replication.
“This additional indication for Baraclude is important news as it is now proven to be an effective treatment option for physicians to help in managing chronic hepatitis B patients with decompensated liver disease,” University of Hawaii professor of medicine Naoky Tsai said.
